FI991197A0 - Neurotrooppiset tekijät lantionalueen ääreishermoston toimintahäiriön hoitamisessa - Google Patents

Neurotrooppiset tekijät lantionalueen ääreishermoston toimintahäiriön hoitamisessa

Info

Publication number
FI991197A0
FI991197A0 FI991197A FI991197A FI991197A0 FI 991197 A0 FI991197 A0 FI 991197A0 FI 991197 A FI991197 A FI 991197A FI 991197 A FI991197 A FI 991197A FI 991197 A0 FI991197 A0 FI 991197A0
Authority
FI
Finland
Prior art keywords
surgery
pelvic
proteins
treatment
penile
Prior art date
Application number
FI991197A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Mart Saarma
Antti Laurikainen
Matti Airaksinen
Jukka Hiltunen
Erik Klinge
Original Assignee
Mart Saarma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mart Saarma filed Critical Mart Saarma
Priority to FI991197A priority Critical patent/FI991197A0/fi
Publication of FI991197A0 publication Critical patent/FI991197A0/fi
Priority to AU47610/00A priority patent/AU776275B2/en
Priority to DE60037111T priority patent/DE60037111T2/de
Priority to JP2000620979A priority patent/JP2003500455A/ja
Priority to PCT/FI2000/000476 priority patent/WO2000072871A1/en
Priority to CN00810917A priority patent/CN1365285A/zh
Priority to IL14634600A priority patent/IL146346A0/xx
Priority to NZ515379A priority patent/NZ515379A/en
Priority to AT00929587T priority patent/ATE378061T1/de
Priority to KR1020017015154A priority patent/KR20020016805A/ko
Priority to EP00929587A priority patent/EP1181042B8/en
Priority to ES00929587T priority patent/ES2295027T3/es
Priority to CA002373726A priority patent/CA2373726A1/en
Priority to NO20015751A priority patent/NO20015751L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
FI991197A 1999-05-27 1999-05-27 Neurotrooppiset tekijät lantionalueen ääreishermoston toimintahäiriön hoitamisessa FI991197A0 (fi)

Priority Applications (14)

Application Number Priority Date Filing Date Title
FI991197A FI991197A0 (fi) 1999-05-27 1999-05-27 Neurotrooppiset tekijät lantionalueen ääreishermoston toimintahäiriön hoitamisessa
CA002373726A CA2373726A1 (en) 1999-05-27 2000-05-26 Neurotrophic factors in the treatment of peripheral nerve dysfunction of pelvic area
IL14634600A IL146346A0 (en) 1999-05-27 2000-05-26 Neurotrophic factors in the treatment of peripheral nerve dysfunction of pelvic area
DE60037111T DE60037111T2 (de) 1999-05-27 2000-05-26 Neurotrophe faktoren zur behandlung von penilen erektilen dysfunktionen
JP2000620979A JP2003500455A (ja) 1999-05-27 2000-05-26 骨盤部の末梢神経機能障害の処置における神経向性因子
PCT/FI2000/000476 WO2000072871A1 (en) 1999-05-27 2000-05-26 Neurotrophic factors in the treatment of peripheral nerve dysfunction of pelvic area
CN00810917A CN1365285A (zh) 1999-05-27 2000-05-26 神经营养因子在骨盆神经丛外周神经功能障碍的治疗中的应用
AU47610/00A AU776275B2 (en) 1999-05-27 2000-05-26 Neurotrophic factors in the treatment of peripheral nerve dysfunction of pelvic area
NZ515379A NZ515379A (en) 1999-05-27 2000-05-26 Neurotrophic factors in the treatment of peripheral nerve dysfunction of pelvic area
AT00929587T ATE378061T1 (de) 1999-05-27 2000-05-26 Neurotrophe faktoren zur behandlung einer dysfunktion peripherer nerven im beckenbereich
KR1020017015154A KR20020016805A (ko) 1999-05-27 2000-05-26 골반부위 말초신경이상 치료에서 신경영양성 인자
EP00929587A EP1181042B8 (en) 1999-05-27 2000-05-26 Neurotrophic factors in the treatment of peripheral nerve dysfunction of pelvic area
ES00929587T ES2295027T3 (es) 1999-05-27 2000-05-26 Factores neurotroficos en el tratamiento de disfunciones de los nervios perifericos del area pelvica.
NO20015751A NO20015751L (no) 1999-05-27 2001-11-26 Nevrotrofiske faktorer i behandlingen av perifer nervedysfunksjon i bekkenområdet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI991197A FI991197A0 (fi) 1999-05-27 1999-05-27 Neurotrooppiset tekijät lantionalueen ääreishermoston toimintahäiriön hoitamisessa

Publications (1)

Publication Number Publication Date
FI991197A0 true FI991197A0 (fi) 1999-05-27

Family

ID=8554739

Family Applications (1)

Application Number Title Priority Date Filing Date
FI991197A FI991197A0 (fi) 1999-05-27 1999-05-27 Neurotrooppiset tekijät lantionalueen ääreishermoston toimintahäiriön hoitamisessa

Country Status (14)

Country Link
EP (1) EP1181042B8 (es)
JP (1) JP2003500455A (es)
KR (1) KR20020016805A (es)
CN (1) CN1365285A (es)
AT (1) ATE378061T1 (es)
AU (1) AU776275B2 (es)
CA (1) CA2373726A1 (es)
DE (1) DE60037111T2 (es)
ES (1) ES2295027T3 (es)
FI (1) FI991197A0 (es)
IL (1) IL146346A0 (es)
NO (1) NO20015751L (es)
NZ (1) NZ515379A (es)
WO (1) WO2000072871A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
AU2001278981A1 (en) 2000-07-21 2002-02-05 Tom F Lue Prevention and treatment of sexual arousal disorders
CA2637707A1 (en) 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist
TW201034684A (en) * 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
DE102011051868B4 (de) * 2011-07-15 2013-02-21 ITM Isotopen Technologien München AG Verfahren zur Herstellung trägerfreier hochreiner 177Lu-Verbindungen sowie trägerfreie 177Lu-Verbindungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020365A1 (en) * 1991-05-21 1992-11-26 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on neurotrophin-4 expression
US6232449B1 (en) * 1996-03-14 2001-05-15 Washington University Persephin and related growth factors
CA2295500A1 (en) * 1996-07-12 1998-01-22 Massachusetts Institute Of Technology Methods of controlling axonal growth
CA2279577A1 (en) * 1997-02-04 1998-08-06 Valentis, Inc. Treatment for urinary incontinence using gene therapy techniques
DE69832797T2 (de) * 1997-02-18 2006-08-17 Genentech, Inc., South San Francisco Neurturin-rezeptor

Also Published As

Publication number Publication date
ATE378061T1 (de) 2007-11-15
IL146346A0 (en) 2002-07-25
AU776275B2 (en) 2004-09-02
KR20020016805A (ko) 2002-03-06
NO20015751L (no) 2001-12-20
WO2000072871A1 (en) 2000-12-07
EP1181042B1 (en) 2007-11-14
EP1181042B8 (en) 2008-01-23
DE60037111D1 (de) 2007-12-27
DE60037111T2 (de) 2008-10-02
EP1181042A1 (en) 2002-02-27
CN1365285A (zh) 2002-08-21
JP2003500455A (ja) 2003-01-07
ES2295027T3 (es) 2008-04-16
CA2373726A1 (en) 2000-12-07
NZ515379A (en) 2004-04-30
NO20015751D0 (no) 2001-11-26
AU4761000A (en) 2000-12-18

Similar Documents

Publication Publication Date Title
HUP9603484A2 (hu) Gyógyászati készítmények és eljárás ingerületátvitel befolyásolására
MXPA02006885A (es) Bloqueo del crecimiento axonal mediado por receptor de nogo.
WO2002041837A3 (en) Treatment of mucositis
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
EA200100664A1 (ru) Способ и устройство для оптимизации имплантации биологического материала
TR199903154T2 (xx) Meme kanserinin tedavisi ve te�hisi i�in bile�imler ve y�ntemler
ATE321856T1 (de) Humane rezeptortyrosinkinase
FI991197A0 (fi) Neurotrooppiset tekijät lantionalueen ääreishermoston toimintahäiriön hoitamisessa
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
EP1114862A3 (de) Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
WO2003103573A3 (en) METHODS OF TREATING A NEUROLOGICAL DISORDER BY PERIPHERAL DELIVERY OF A TROPHIC FACTOR
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
ATE255411T1 (de) Hyaluronsäurerezeptoren bindende stoffe und deren verwendung zur behandlung von tumoren und restenose
WO2001012127A3 (en) TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
MX9707617A (es) Factor de crecimiento de criptina humano.
Hayase et al. A Case of Blunt Traumatic Arteriovenous Malformation of the Forearm
RU2493862C2 (ru) Способ лечения хронических заболеваний
WO2003004527A3 (en) Novel neurotrophic factors
SU1725920A1 (ru) Способ изгнани конкрементов из верхних мочевых путей
MD1732G2 (ro) Metodă de pronostic al evoluţiei bolii ulceroase duodenale
RU97100004A (ru) Способ коррекции и лечения заболеваний, вызванных родовыми черепно- мозговыми травмами
Kawagoe et al. The Recuperation Research of the Patients Operated for Femoral Neck Fracture
RU97120247A (ru) Способ лечения флегмоны кисти
EA200001091A1 (ru) Способ лечения заболеваний, связанных с образованием конкрементов